Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 1 7Phase 1/2 6Phase 3 3Phase NA 2Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 2

Interventions

Exercise 419Blood Specimen Collection 319Standard of Care 299Surveys and Questionnaires 242Radiosurgery 239Magnetic Resonance Spectroscopy 232Educational Status 223Methods 221Radiotherapy 216Early Intervention, Educational 200Interviews as Topic 142Practice Guidelines as Topic 141Biopsy 125Surgical Procedures, Operative 119Drug Therapy 119Acupuncture Therapy 119Control Groups 115Therapeutics 101Palliative Care 97Resistance Training 94Counseling 88Saline Solution 87Magnetic Resonance Imaging 84Cyclophosphamide 83Specimen Handling 73Cisplatin 73Radiofrequency Ablation 71Cognitive Behavioral Therapy 71Radiotherapy, Intensity-Modulated 68Colonoscopy 65

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × OTHER × lutetium Lu 177 dotatate × Clear all
NCT02743741 2025-12-03

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

University Health Network, Toronto

Phase NA Active not recruiting
195 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05513469 2023-04-07

Radio-Marker

Erasmus Medical Center

Phase NA Unknown
20 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡